Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced today that it has entered a scientific research collaboration agreement with GemVCare (referred to as GVC), a Hong Kong-based biotechnology enterprise. Leveraging their respective core strengths, the two parties will conduct joint clinical trial and real-world research using dorzagliatin (trade name: MYHOMSIS®, 華領片®)
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (trade name in Macao: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region for the treatment of Type 2 diabetes in adults.
Hua Medicine and DKSH Hong Kong announced the expansion of their strategic partnership to accelerate patient access to innovative drug therapies in Hong Kong. The partnership brings together Hua Medicine's expertise in metabolic disease drug development and DKSH's integrated market expansion capabilities to deliver long-term value and meaningful healthcare impact across the region.
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
沪公网安备 31011502013809号 Privacy Statement Terms of Use
